Nivetha Brathaban

Nivetha Brathaban

Auto-generated profile, based on publicly available information

Nivetha Brathaban

Nurix Therapeutics, Brisbane, California

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2026 in Cancer Discovery
Verified
Journal Article
Open access
QSQuinlan Sievers
Quinlan Sievers
HLHao Lu
Hao Lu
ACAllison Cool
Allison Cool
SGStefan Gajewski
Stefan Gajewski
TKTim Kong
Tim Kong
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor–resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown. In this study, we sequenced serial CLL samples from patients enrolled in phase I trials of zelebrudomide and bexobrutideg and observed recurrent expansion of preexisting BTKA428D mutations at relapse. Unlike previously studied BTK inhibitor resistance mutations, BTKA428D conferred pan-resistance to BTK inhibitors and degraders. In the absence of BTK-directed therapies, however, cells bearing BTKA428D exhibited a competitive disadvantage. A crystal structure of BTKA428D revealed that the mutant aspartate clashes with the adenine ring of adenosine triphosphate and the adenine-mimetic moiety of BTK inhibitors and degraders. Combining BTK degraders with venetoclax mitigated the expansion of BTKA428D. These results provide the molecular basis for clinical resistance to BTK degraders and will inform the development of next-generation BTK degrader therapies. Significance: BTK degraders are a promising new therapy for CLL. We demonstrate that BTKA428D is a recurrent BTK degrader resistance mutation in patients that confers pan-resistance to BTK inhibitors and degraders due to steric clash with their shared, adenine-mimetic moiety. Understanding this mutation can guide the development of next-generation BTK degraders.

27 February 2026 in JMIRx Bio
Verified
Journal Article
Open access
NBNivetha Brathaban
Nivetha Brathaban
This is a peer review report related to "Localized Immune Cascade Programming in Desmoplastic Tumors: In Silico-Validated, Literature-Anchored Systems-Level Model"

4 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMark Noviski
Mark Noviski
PAPaul Auger
Paul Auger
DBDanielle Bautista
Danielle Bautista
NBNivetha Brathaban
Nivetha Brathaban
BBBrandon Bravo
Brandon Bravo
FCFrederick Cohen
Frederick Cohen
Bruton’s tyrosine kinase (BTK) transduces B-cell receptor (BCR), Toll-like receptor (TLR), and Fc receptor (FcR) signaling, and overactivation of these pathways drives B-cell malignancies and antibody-mediated autoimmune disease. Small molecule inhibitors block the enzymatic functions of BTK, but this inhibition is undermined by resistance mutations, several of which abolish BTK’s kinase activity yet promote oncogenic signaling through BTK scaffolding functions. We report the discovery and characterization of bexobrutideg (NX-5948), a heterobifunctional degrader that recruits cereblon (CRBN) to selectively degrade BTK while sparing molecular glue neosubstrates. We demonstrate that bexobrutideg acts catalytically, degrading thousands of copies of BTK per molecule per hour, and this event-driven pharmacology renders it resilient to mutations that confer resistance to both covalent- and noncovalent-inhibitors. Bexobrutideg is orally bioavailable, driving deep and durable BTK degradation across species. Bexobrutideg demonstrates strong efficacy in wild-type and ibrutinib-resistant lymphoma models and robustly suppresses pathway activation in models of autoimmune disease.